An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice - PubMed (original) (raw)
. 1997 Feb;280(2):988-1000.
Affiliations
- PMID: 9023316
An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice
C F Bennett et al. J Pharmacol Exp Ther. 1997 Feb.
Abstract
Mice treated p.o. with 5% dextran sodium sulfate develop a mild to moderate colitis characterized by focal areas of inflammation and crypt abscesses. Immunohistological analysis of colons from dextran sodium sulfate-treated mice revealed an increased expression of intercellular adhesion molecule 1 (ICAM-1) and infiltration of lymphocyte function antigen 1-positive cells. A murine-specific antisense oligonucleotide, ISIS 3082, was used to determine the role of ICAM-1 expression in the development of colitis. Prophylactic treatment of dextran sodium sulfate-treated mice with ISIS 3082 reduced the clinical signs of colitis in a dose-dependent manner, with maximal effects occurring at a dose of 1 mg/kg/day. Reductions in ICAM-1 immunostaining and infiltrating leukocytes were observed in colons of animals treated with 1 mg/kg ISIS 3082. Scrambled control oligonucleotides failed to modify the course of the disease. The ICAM-1 oligonucleotide also diminished the clinical severity of colitis in mice with established colitis. The toxicity of ISIS 3082 was assessed in normal CD-1 mice by administering the oligonucleotide intravenously every other day for 2 weeks. At pharmacologically relevant doses of ISIS 3082 (1 and 10 mg/kg), there were no signs of toxicity with respect to body and organ weights, clinical chemistry or hematology. At a dose of oligonucleotide 20- to 100-fold greater than maximal pharmacological doses, the oligonucleotide produced an increase in liver and spleen weights; a mild chronic inflammation in liver, lung and lymph nodes; monocytosis and an elevation of serum liver transaminases. These data suggest that an antisense oligonucleotide that reduces ICAM-1 expression could be effective in the therapy of inflammatory bowel disease in humans and that such an oligonucleotide would be safe at pharmacologically relevant doses.
Similar articles
- Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis.
Myers KJ, Murthy S, Flanigan A, Witchell DR, Butler M, Murray S, Siwkowski A, Goodfellow D, Madsen K, Baker B. Myers KJ, et al. J Pharmacol Exp Ther. 2003 Jan;304(1):411-24. doi: 10.1124/jpet.102.040329. J Pharmacol Exp Ther. 2003. PMID: 12490618 - Amelioration of chronic and spontaneous intestinal inflammation with an antisense oligonucleotide (ISIS 9125) to intracellular adhesion molecule-1 in the HLA-B27/beta2 microglobulin transgenic rat model.
Bowen-Yacyshyn MB, Bennett CF, Nation N, Rayner D, Yacyshyn BR. Bowen-Yacyshyn MB, et al. J Pharmacol Exp Ther. 2002 Sep;302(3):908-17. doi: 10.1124/jpet.102.036053. J Pharmacol Exp Ther. 2002. PMID: 12183646 - Efficacy of an inhibitor of adhesion molecule expression (GI270384X) in the treatment of experimental colitis.
Panés J, Aceituno M, Gil F, Miquel R, Piqué JM, Salas A, McLean P. Panés J, et al. Am J Physiol Gastrointest Liver Physiol. 2007 Oct;293(4):G739-48. doi: 10.1152/ajpgi.00059.2007. Epub 2007 Jul 26. Am J Physiol Gastrointest Liver Physiol. 2007. PMID: 17656448 - Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.
Henry SP, Templin MV, Gillett N, Rojko J, Levin AA. Henry SP, et al. Toxicol Pathol. 1999 Jan-Feb;27(1):95-100. doi: 10.1177/019262339902700117. Toxicol Pathol. 1999. PMID: 10367680 Review. - Antiadhesion molecule therapy in inflammatory bowel disease.
van Assche G, Rutgeerts P. van Assche G, et al. Inflamm Bowel Dis. 2002 Jul;8(4):291-300. doi: 10.1097/00054725-200207000-00009. Inflamm Bowel Dis. 2002. PMID: 12131614 Review.
Cited by
- A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response.
Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD. Su CG, et al. J Clin Invest. 1999 Aug;104(4):383-9. doi: 10.1172/JCI7145. J Clin Invest. 1999. PMID: 10449430 Free PMC article. - Colonic epithelial cells induce endothelial cell expression of ICAM-1 and VCAM-1 by a NF-kappaB-dependent mechanism.
Maaser C, Schoeppner S, Kucharzik T, Kraft M, Schoenherr E, Domschke W, Luegering N. Maaser C, et al. Clin Exp Immunol. 2001 May;124(2):208-13. doi: 10.1046/j.1365-2249.2001.01541.x. Clin Exp Immunol. 2001. PMID: 11422196 Free PMC article. - Targeting leukocyte trafficking for the treatment of inflammatory bowel disease.
Arseneau KO, Cominelli F. Arseneau KO, et al. Clin Pharmacol Ther. 2015 Jan;97(1):22-8. doi: 10.1002/cpt.6. Epub 2014 Dec 2. Clin Pharmacol Ther. 2015. PMID: 25670380 Free PMC article. Review. - Shining a light on intestinal traffic.
Murphy CT, Nally K, Shanahan F, Melgar S. Murphy CT, et al. Clin Dev Immunol. 2012;2012:808157. doi: 10.1155/2012/808157. Epub 2011 Nov 22. Clin Dev Immunol. 2012. PMID: 22162719 Free PMC article. Review. - Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR; ISIS 2302-CS9 Investigators. Yacyshyn BR, et al. Gut. 2002 Jul;51(1):30-6. doi: 10.1136/gut.51.1.30. Gut. 2002. PMID: 12077088 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous